Abiomed Receives Reimbursement Approval for Impella in The Netherlands

Published: May 28, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DANVERS, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Netherlands has approved new reimbursement coding and payment for the Impella product. The new coding allows for hospitals to receive funding for the use of the Impella technology in a broad set of clinical indications of heart disease through the process known as Diagnosis Treatment Combinations (Diagnose Behandeling Combinaties; DBCs), similar to the Medicare Diagnosis-Related Group (DRG) system in the United States.

Help employers find you! Check out all the jobs and post your resume.

Back to news